The notices it replaced
- Reissues: PAR-21-252 Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)
- 2 steps back: PAR-19-098 Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)
- 3 steps back: PAR-17-001 Emerging Global Leader Award (K43)
- 4 steps back: PAR-15-292 Emerging Global Leader Award (K43)
Who won it before
94 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $9,256,777 in first-year total cost, median $99,512.
Most frequent study sections
- International and Cooperative Projects - 1 Study Section[ICP1]56
- Special Emphasis Panel[ZRG1 ICP-P (55)]16
- Special Emphasis Panel[ZRG1 ICP-J (55)]10
- Special Emphasis Panel[ZRG1 ICP-L (57)]7
- Special Emphasis Panel[ZRG1 BDA-A (90)]3
Most frequent institutions
- STELLENBOSCH UNIVERSITY9
- UNIVERSITY OF CAPE TOWN7
- MBARARA UNIVERSITY/SCIENCE/ TECHNOLOGY5
- COLLEGE OF MEDICINE, UNIVERSITY OF IBADAN4
- COLLEGE OF MEDICINE, UNIVERSITY OF LAGOS4
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Characterizing the Cyclic-di-AMP Pathway in Clostridioides difficile1K43TW013094-01 | PHANCHANA, MATTHEW | MAHIDOL UNIVERSITY | $151,200 | ZRG1 |
| 2025 | Investigating the sequelae of pulmonary tuberculosis in Gambian children and adolescents1K43TW013130-01 | NKEREUWEM, ESIN | MEDICAL RESEARCH COUNCIL UNIT THE GAMBIA AT THE LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE | $136,718 | ZRG1 |
| 2025 | Decentralizing Breast Biopsy Procedures for Early Cancer Diagnosis In Rwanda1K43TW013123-01 | ALAYANDE, BARNABAS TOBI | UNIVERSITY OF GLOBAL HEALTH EQUITY | $131,278 | ZRG1 |
| 2025 | Clonotyping Airway T-cells to Uncover Microbiome-Specific Inflammotypes in HIV-associated COPD1K43TW013092-01 | KAYONGO, ALEX | MAKERERE UNIVERSITY LUNG INSTITUTE LIMITED | $124,524 | ZRG1 |
| 2024 | Finding a pathway to HIV cure among adolescents on long-standing ART in Botswana through reservoir analysis, analytic treatment interruption, and biomarker assessment1K43TW012848-01 · under PAR-21-252 | KOOFHETHILE, CATHERINE KEGAKILWE | BOTSWANA-HARVARD AIDS INSTITUTE | $113,400 | ZRG1 |
| 2024 | Metabolomic predictors of weight gain during pregnancy and the postpartum period in South African women living with HIV1K43TW012887-01 · under PAR-21-252 | MADLALA , HLENGIWE | UNIVERSITY OF CAPE TOWN | $113,048 | ZRG1 |
| 2024 | Development of a smart transformable nanotherapeutic against cancers with acquired resistance to EGFR-targeted therapies caused by MET amplification1K43TW012787-01 · under PAR-21-252 | MAHALAPBUTR, PANUPONG | KHON KAEN UNIVERSITY | $112,974 | ZRG1 |
| 2024 | Molecular and cellular underpinnings of placental malaria1K43TW012799-01 · under PAR-21-252 | KOBIA, FRANCIS MUNGATHIA | MOUNT KENYA UNIVERSITY | $111,024 | ZRG1 |
| 2024 | Mycobacterial Epigenetics: Investigating the impact of DNA methylation on antibiotic tolerance and persistence1K43TW012786-01 · under PAR-21-252 | KRIEL, NASTASSJA LISE | STELLENBOSCH UNIVERSITY | $106,160 | ZRG1 |
| 2024 | Bifidobacterium infantis supplementation in early life to improve neurodevelopment in infants exposed to HIV1K43TW012864-01 · under PAR-21-252 | HAPPEL, ANNA-URSULA | UNIVERSITY OF CAPE TOWN | $101,762 | ZRG1 |
| 2024 | Cardiovascular magnetic resonance assessment of subclinicalcardiovascular abnormalities before and after the initiation of antiretroviral therapy in HIV-infected South Africans1K43TW012849-01 · under PAR-21-252 | ROBBERTSE, PIETER-PAUL STRAUSS | STELLENBOSCH UNIVERSITY | $100,559 | ZRG1 |
| 2024 | Pericoronary Adipose Tissue, Inflammation, and Subclinical Coronary Artery Disease in People with HIV in Uganda1K43TW012846-01 · under PAR-21-252 | BIBANGAMBAH, PROSSY KYASIMIRE | MBARARA UNIVERSITY/SCIENCE/ TECHNOLOGY | $99,384 | ZRG1 |
| 2024 | Adapting evidence-based stigma reduction interventions to address HIV and drug use stigma among family members of people who use drugs1K43TW012859-01 · under PAR-21-252 | MLUNDE, LINDA BEATRICE | MUHIMBILI UNIVERSITY/ ALLIED HLTH SCIS | $98,996 | ZRG1 |
| 2024 | Unravelling the role of gene therapy on spinal disc mediated low back pain1K43TW012780-01 · under PAR-21-252 | OGUNLADE, BABATUNDE | THE FEDERAL UNIVERSITY OF TECHNOLOGY, AKURE, NIGERIA | $95,684 | ZRG1 |
| 2024 | Improving dog vaccinations: a development and feasibility study to pave the way for effective, synchronized dog vaccination campaigns in Africa1K43TW012582-01A1 · under PAR-21-252 | MAGANGA, SAMBO | IFAKARA HEALTH INSTITUTE | $93,127 | ZRG1 |
| 2024 | Microbiome profiling of non-healing filarial lymphedema wounds in Ghana.1K43TW012795-01 · under PAR-21-252 | KWARTENG, ALEXANDER | KWAME NKRUMAH UNIVERSITY/SCIENCE/TECH | $89,534 | ZRG1 |
| 2023 | Use of Peripheral Blood Mononuclear Cells Mitochondrial DNA Content to Detect Hepatocellular Carcinoma in Hepatitis B Virus Infected Nigerians.1K43TW012589-01 · under PAR-21-252 | ADISA, RAHMAT ADETUTU | COLLEGE OF MEDICINE, UNIVERSITY OF LAGOS | $117,021 | ZRG1 |
| 2023 | Community-based Medication Adherence Support for Older Adults Living with HIV and Hypertension (CBA Intervention)1K43TW012641-01 · under PAR-21-252 | KIPLAGAT, JEPCHIRCHIR | MOI UNIVERSITY COLLEGE OF HEALTH SCIENCES | $113,401 | ZRG1 |
| 2023 | Investigating the contribution of geographic accessibility and vaccine delivery channels to untimely measles vaccination and zero-dose prevalence in The Gambia: implications for disease outbreaks1K43TW012574-01 · under PAR-21-252 | WARIRI, OGHENEBRUME | MEDICAL RESEARCH COUNCIL UNIT THE GAMBIA AT THE LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE | $113,291 | ZRG1 |
| 2023 | Insulin-like Growth Factor-1 (IGF-1) signalling in immunometabolism of TB and TB-Diabetes comorbidity1K43TW012587-01 · under PAR-21-252 | PARIHAR, SURAJ P. | UNIVERSITY OF CAPE TOWN | $112,586 | ZRG1 |
| 2023 | Exposure to Mixtures of Emerging Contaminants in the Environment - Are Communities in Uganda at Health Risk?- A Case Study of Mbarara City.1K43TW012594-01 · under PAR-21-252 | BIRUNGI, GRACE | MBARARA UNIVERSITY/SCIENCE/ TECHNOLOGY | $108,103 | ZRG1 |
| 2023 | Development of a Next-generation Rapid Phenotypic Assay for Drug-Resistant M. tuberculosis1K43TW012591-01 · under PAR-21-252 | KLOPPER, MARISA | STELLENBOSCH UNIVERSITY | $105,893 | ZRG1 |
| 2023 | A comprehensive whole genome sequence scan for positive selection in southern Africa1K43TW012577-01 · under PAR-21-252 | UREN, CAITLIN | STELLENBOSCH UNIVERSITY | $97,404 | ZRG1 |
| 2023 | Delineating the kidney brain axis in children with severe malaria (KID-BRAIN)1K43TW012586-01 · under PAR-21-252 | BATTE, ANTHONY | MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES | $96,471 | ZRG1 |
| 2023 | Clinical decision support algorithm to optimize management of respiratory tract infection in children attending primary health facilities in Kilimanjaro Region, Tanzania1K43TW012585-01 · under PAR-21-252 | NGOCHO, JAMES SAMWEL | KILIMANJARO CHRISTIAN MEDICAL CENTRE | $78,012 | ZRG1 |
| 2023 | Use of Pharmacoepidemiology to Understand Predictors and Impact of Low-level Viremia in Persons with HIV in West Africa1K43TW012648-01 · under PAR-21-252 | HERBERTSON, EBIERE CLARA | NIGERIAN INSTITUTE OF MEDICAL RESEARCH | $65,433 | ZRG1 |
| 2022 | Genomic Epidemiology of Campylobacter in Poultry to Enable the Effective Control of Human Campylobacteriosis in a Middle Income Country1K43TW012298-01 · under PAR-21-252 | SCHIAFFINO, FRANCESCA | UNIVERSIDAD PERUANA CAYETANO HEREDIA | $152,280 | ZRG1 |
| 2022 | Viral Diversity an Innovative Biomarker for Refining Estimates of HIV Incidence1K43TW012350-01 · under PAR-21-252 | MOYO, SIKHULILE | BOTSWANA-HARVARD AIDS INSTITUTE | $136,526 | ZRG1 |
| 2022 | Male Access to Sexual Health Services and PrEP1K43TW012362-01 · under PAR-21-252 | SMITH, PHILIP JOHN | DESMOND TUTU HIV FOUNDATION | $106,618 | ZRG1 |
| 2022 | Developmental neurotoxicity and autism spectrum disorder1K43TW011920-01A1 · under PAR-21-252 | IJOMONE, OMAMUYOVWI MEASHACK | THE FEDERAL UNIVERSITY OF TECHNOLOGY, AKURE, NIGERIA | $95,917 | ZRG1 |
| 2022 | COMParative ASSessment of p16/Ki-67 DUal Staining Technology in women living with HIV (COMPASS-DUST study)1K43TW011930-01A1 · under PAR-21-252 | OKUNADE, KEHINDE SHARAFADEEN | COLLEGE OF MEDICINE, UNIVERSITY OF LAGOS | $95,239 | ZRG1 |
| 2022 | Longitudinal microbiome-host interactions and clinical outcomes in drug-resistant tuberculosis patients1K43TW012302-01 · under PAR-21-252 | NAIDOO, CHARISSA CAMILLE | STELLENBOSCH UNIVERSITY | $89,667 | ZRG1 |
| 2022 | Early life aflatoxin B1 exposure and epigenetic programming in Nigerian Newborns1K43TW011942-01A1 · under PAR-21-252 | ROTIMI, OLUWAKEMI ANUOLUWAPO | COVENANT UNIVERSITY | $81,631 | ZRG1 |
| 2022 | PRENATAL FINE PARTICULATE MATTER (PM2.5) AND POLYCYCLIC AROMATIC HYDROCARBON (PAH) EXPOSURES AND THEIR ASSOCIATION WITH BIRTHWEIGHT IN SOUTHERN INDIA1K43TW011408-01A1 · under PAR-19-098 | PUTTASWAMY, NAVEEN | SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH TRUST | $61,690 | ICP1 |
| 2021 | Multi-target approach to rational design of novel therapeutics for human African trypanosomiasis1K43TW012015-01 · under PAR-19-098 | BALOGUN, EMMANUEL OLUWADARE | AHMADU BELLO UNIVERSITY | $115,344 | ICP1 |
| 2021 | Leveraging existing HIV differentiated service delivery models to screen and treat hypertension in Ugandan persons living with HIV for dual control1K43TW011963-01 · under PAR-19-098 | MUDDU, MARTIN | INFECTIOUS DISEASES RES COLLABORATION | $113,400 | ICP1 |
| 2021 | TESTING A LAY COUNSELOR-LED PrEP DELIVERY MODEL IN PUBLIC HEALTH FACILITIES IN KENYA1K43TW011940-01 · under PAR-19-098 | IRUNGU, ELIZABETH MUGOIRI | KENYA MEDICAL RESEARCH INSTITUTE (KEMRI) | $111,860 | ICP1 |
| 2021 | Defining the biology of HIV-associated aggressive B-cell lymphoma in Southern Africa1K43TW011986-01 · under PAR-19-098 | ANTEL, KATHERINE | UNIVERSITY OF CAPE TOWN | $110,505 | ICP1 |
| 2021 | Quantifying, Explaining and Predicting Survival After Diagnosis of HIV-related Kaposi Sarcoma in East Africa1K43TW011987-01 · under PAR-19-098 | BYAKWAGA, HELEN | INFECTIOUS DISEASES INSTITUTE | $102,914 | ICP1 |
| 2021 | Epidemiology of Malaria Invasion in Mutare City and Targets for Elimination, Zimbabwe1K43TW011414-01A1 · under PAR-19-098 | MHARAKURWA, SUNGANO | AFRICA UNIVERSITY | $102,136 | ICP1 |
| 2021 | Development of a Multiplex Quantitative PCR Assay for HIV and Hepatitis B Virus, for Low- and middle Income Countries1K43TW011957-01 · under PAR-19-098 | FOFANA, DJENEBA BOCAR | UNIV OF SCIENCES, TECH & TECH OF BAMAKO | $99,640 | ICP1 |
| 2021 | Epigenetic Influence of Diet on Bladder Physiology1K43TW011932-01 · under PAR-19-098 | ADEDEJI, TEMITOPE GABRIEL | THE FEDERAL UNIVERSITY OF TECHNOLOGY, AKURE, NIGERIA | $94,938 | ICP1 |
| 2021 | Prevalence and temporal dynamics of clonal mutations associated with the risk of hematological cancer in a cohort of clinically healthy Nigerians1K43TW011926-01 · under PAR-19-098 | OYEBOLA, KOLAPO | NIGERIAN INSTITUTE OF MEDICAL RESEARCH | $93,106 | ICP1 |
| 2021 | A mixed-methods sequential explanatory study to examine the implementation landscape for evidence-based transdiagnostic approaches for mental disorders in primary healthcare in Ukraine.1K43TW012016-01 · under PAR-19-098 | MAZHNAIA, ALONA | KYEVO-MOGYLYANSKA AKADEMIYA, NATSIONALNY UNIVERSYTET | $89,100 | ICP1 |
| 2021 | Children's Exposure to Indoor and Outdoor Air Pollution within the SHEAR Project in Rwanda1K43TW011954-01 · under PAR-19-098 | KALISA, EGIDE | NATIONAL UNIVERSITY OF RWANDA | $79,432 | ICP1 |
| 2021 | A clinical prediction rule for identifying South African colorectal cancer patients who will fail to engage in oncology care1K43CA268978-01 · under PAR-19-098 | MOODLEY, YOSHAN | UNIVERSITY OF KWAZULU-NATAL | $58,959 | ICP1 |
| 2020 | Understanding the role of schools in supporting HIV treatment outcomes among HIV infected adolescents1K43TW011422-01A1 · under PAR-19-098 | NJUGUNA, IRENE NYAMBURA | KENYATTA NATIONAL HOSPITAL | $122,747 | ICP1 |
| 2020 | The long-term consequences of pulmonary tuberculosis and respiratory viruses on lung health in young South African children1K43TW011028-01A1 · under PAR-19-098 | VAN DER ZALM, MARIEKE MARGREET | STELLENBOSCH UNIVERSITY | $113,252 | ICP1 |
| 2020 | Novel Prostate Cancer Cell Lines to Address Prostate Cancer Disparity in Black Men1K43TW011387-01A1 · under PAR-19-098 | BADAL, SIMONE ANNMARIE | UNIVERSITY OF THE WEST INDIES | $111,236 | ICP1 |
| 2020 | Impact of asymptomatic sexually transmitted infections and interferon agonists on the susceptibility of foreskin primary cells to HIV-1 infection.1K43TW011436-01A1 · under PAR-19-098 | CHIGORIMBO-TSIKIWA, NYARADZO TSITSI | UNIVERSITY OF CAPE TOWN | $109,406 | ICP1 |
| 2020 | Interdisciplinary and multi-level approach to estimate the disease burden and outcomes of childhood tuberculous meningitis.1K43TW011006-01A1 · under PAR-17-001 | DU PREEZ, KAREN | STELLENBOSCH UNIVERSITY | $100,603 | ICP1 |
| 2020 | Dysregulation of the Human Ubiquitin Proteasome System in Pediatric Severe Malarial Anemia1K43TW011581-01 · under PAR-19-098 | ANYONA, SAMUEL BONUKE | MASENO UNIVERSITY | $68,953 | ICP1 |
| 2020 | Effect of Community Wide Deworming on Hookworm Modulated Immune Responses to Bystander Antigens and Vaccines in Southern India1K43TW011415-01 · under PAR-17-001 | AJJAMPUR, SITARA SWARNA RAO | CHRISTIAN MEDICAL COLLEGE | $64,800 | ZRG1 |
| 2019 | Dolutegravir for the treatment of HIV in patients with Tuberculosis in KwaZulu-Natal South Africa1K43TW011437-01 · under PAR-17-001 | NAIDOO, ANUSHKA | CENTRE/AIDS PROGRAMME/RES/SOUTH AFRICA | $102,834 | ICP1 |
| 2019 | Responding to the challenges of Adolescent Perinatal Depression with patient-centered mobile health1K43TW011046-01A1 · under PAR-17-001 | KOLA, LOLA | COLLEGE OF MEDICINE, UNIVERSITY OF IBADAN | $99,857 | ICP1 |
| 2019 | Oxygen sensing mechanism(s) in fetal programming of salt-sensitive hypertension1K43TW011009-01A1 · under PAR-17-001 | OLOYO, AHMED KOLADE | COLLEGE OF MEDICINE, UNIVERSITY OF LAGOS | $96,056 | ICP1 |
| 2019 | Vaginal Microbiome in Cervical Intraepithelial Neoplasia and Cancer1K43TW011416-01 · under PAR-17-001 | MUSA, JONAH | UNIVERSITY OF JOS | $92,988 | ZRG1 |
| 2019 | "Plasma and cellular immune biomarkers of Kaposi's sarcoma in HIV-1 suppressed patients"1K43TW011418-01 · under PAR-17-001 | LIDENGE, SALUM JUMA | MUHIMBILI UNIVERSITY/ ALLIED HLTH SCIS | $92,175 | ZRG1 |
| 2019 | Elucidating Cleft Etiology Employing Multiplex and Twin Families (ElCEEMuTF)1K43DE029427-01 · under PAR-17-001 | GOWANS, LORD JEPHTHAH JOOJO | KWAME NKRUMAH UNIVERSITY/SCIENCE/TECH | $91,253 | ICP1 |
| 2019 | The role of HbF decline and its determinants on Sickle Cell Disease expression in the first three years of life.1K43TW011167-01A1 · under PAR-17-001 | NKYA, SIANA WATOKY | MUHIMBILI UNIVERSITY/ ALLIED HLTH SCIS | $88,940 | ICP1 |
| 2019 | The Role of Sex Steroid Hormones in CD4+ T Cell-mediated Immune Responses to Tuberculosis1K43TW011426-01 · under PAR-17-001 | DABITAO, DJENEBA | UNIV OF SCIENCES, TECH & TECH OF BAMAKO | $85,664 | ZRG1 |
| 2019 | Defining Campylobacter and immune response related determinants in the pathogenesis of Guillain-Barré syndrome patients in low-income countries1K43TW011447-01 · under PAR-17-001 | ISLAM, ZHAHIRUL | INTERNATIONAL CTR/DIARRHOEAL DIS RES | $85,249 | ICP1 |
| 2019 | Undetectable and Untransmittable: reducing HIV transmission among young women living with HIV, their partners and children in South Africa1K43TW011434-01 · under PAR-17-001 | TOSKA, ELONA | UNIVERSITY OF CAPE TOWN | $85,034 | ICP1 |
| 2019 | Developing and testing Collaborative Quality ImProvement initiative (C-QIP) for prevention of cardiovascular disease in India1K43TW011164-01 · under PAR-17-001 | SINGH, KAVITA | PUBLIC HEALTH FOUNDATION OF INDIA | $69,249 | ICP1 |
| 2019 | Host defense against Shigella flexneri1K43TW011441-01 · under PAR-17-001 | NOOR, ZANNATUN | INTERNATIONAL CTR/DIARRHOEAL DIS RES | $61,227 | ZRG1 |
| 2018 | Patient-centered intervention to prevent tuberculosis among children < 5 years old1K43TW011137-01 · under PAR-17-001 | OTERO, LARISSA | UNIVERSIDAD PERUANA CAYETANO HEREDIA | $128,325 | ICP1 |
| 2018 | IMmune-mediated Adverse drug Reactions In African HIV endemic setting (IMARI-SA study)1K43TW011178-01 · under PAR-17-001 | PETER, JONATHAN | UNIVERSITY OF CAPE TOWN LUNG INSTITUTE | $113,400 | ICP1 |
| 2018 | Feasibility and acceptability of Enhanced Patient Care (EPC) for adult HIV patients with unsuppressed viral loads in western Kenya1K43TW010684-01A1 · under PAR-17-001 | WACHIRA, JUDDY | MOI UNIVERSITY COLLEGE OF HEALTH SCIENCES | $110,642 | ICP1 |
| 2018 | Patient-centered mobile technology interventions to improve maternal health in Uganda1K43TW011004-01 · under PAR-17-001 | ATUKUNDA, ESTHER CATHYLN | MBARARA UNIVERSITY/SCIENCE/ TECHNOLOGY | $108,567 | ICP1 |
| 2018 | Investigation of responses to Mycobacterium tuberculosis complex lineages by different African host population: Implications for host-directed therapies1K43TW011125-01 · under PAR-17-001 | TIENTCHEU DJOMKAM, LEOPOLD | MEDICAL RESEARCH COUNCIL UNIT THE GAMBIA AT THE LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE | $106,087 | ICP1 |
| 2018 | Implementing mental health interventions for pregnant adolescents in primary care LMIC contexts1K43TW010716-01A1 · under PAR-17-001 | KUMAR, MANASI | UNIVERSITY OF NAIROBI | $102,600 | ICP1 |
| 2018 | Changing the Culture of Disrespect and Abuse in Maternity Care in Kumasi, Ghana1K43TW011022-01 · under PAR-17-001 | DZOMEKU, VERONICA MILLICENT | KWAME NKRUMAH UNIVERSITY/SCIENCE/TECH | $86,584 | ICP1 |
| 2018 | Biomarkers of Kaposi sarcoma recrudescence in Zambia1K43TW011095-01 · under PAR-17-001 | NGALAMIKA, OWEN | UNIVERSITY OF ZAMBIA | $80,029 | ICP1 |
| 2018 | Treatment response and microRNA profiles in triple negative breast cancer patients receiving standard chemotherapy (TARMAC)1K43TW010721-01A1 · under PAR-17-001 | NTEKIM, ATARA ISAIAH | COLLEGE OF MEDICINE, UNIVERSITY OF IBADAN | $74,125 | ICP1 |
| 2018 | APOL1 and increased risk of Preeclampsia in West Africa1K43TW011160-01 · under PAR-17-001 | OSAFO, CHARLOTTE | COLLEGE OF HEALTH SCIENCES, UNIVERSITY OF GHANA | $68,167 | ICP1 |
| 2017 | Developing a care bundle for neonatal sepsis prevention in low-resource settings1K43TW010682-01 · under PAR-17-001 | DRAMOWSKI, ANGELA | STELLENBOSCH UNIVERSITY | $113,400 | ICP1 |
| 2017 | The effect of hypertensive disorders in pregnancy and HIV-infection on maternal, birth and infant outcomes in South Africa1K43TW010683-01 · under PAR-17-001 | SLOGROVE, AMY LOUISE | STELLENBOSCH UNIVERSITY | $112,530 | ICP1 |
| 2017 | HIV Self Testing to Empower Prevention Choices in Sex Workers1K43TW010695-01 · under PAR-17-001 | MUJUGIRA, ANDREW | INFECTIOUS DISEASES INSTITUTE | $108,863 | ICP1 |
| 2017 | Endocrine and metabolic diseases in rural South Africa-establishing burden and improving detection1K43TW010698-01 · under PAR-17-001 | WADE, ALISHA NICOLE | WITS HEALTH CONSORTIUM (PTY), LTD | $105,314 | ICP1 |
| 2017 | Impact of malaria control interventions on the infectious reservoir, host immunity, and drug resistance in Uganda1K43TW010365-01A1 · under PAR-17-001 | NANKABIRWA, JOANITER IMMACULATE | INFECTIOUS DISEASES RES COLLABORATION | $102,911 | ICP1 |
| 2017 | Epidemiology, Immunopathogenesis, and Outcomes of Non-traumatic Spinal Cord Injury in Uganda1K43TW010718-01 · under PAR-17-001 | MUSUBIRE, ABDU KISEKKA | INFECTIOUS DISEASES INSTITUTE | $98,622 | ICP1 |
| 2017 | Seizure frequency, Quality of Life and stigma reduction in people living with epilepsy1K43TW010401-01A1 · under PAR-17-001 | KADDUMUKASA, MARK | MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES | $96,552 | ICP1 |
| 2017 | Promoting Physical Activity and Healthy Eating Among Adults in a Faith-Based Setting In Lagos, Nigeria.1K43TW010704-01 · under PAR-17-001 | ODUKOYA, OLUWAKEMI | COLLEGE OF MEDICINE, UNIVERSITY OF LAGOS | $96,477 | ICP1 |
| 2017 | Polycyclic aromatic hydrocarbons exposure and dietary risk of Esophageal squamous cell carcinoma in Uganda1K43TW010715-01 · under PAR-17-001 | OKELLO, SAMSON | MBARARA UNIVERSITY/SCIENCE/ TECHNOLOGY | $90,570 | ICP1 |
| 2017 | Genetic Testing for Accurate Diabetes Differentiation in Nigeria1K43TW010720-01 · under PAR-17-001 | BALOGUN, WILLIAMS ONABUMEH | COLLEGE OF MEDICINE, UNIVERSITY OF IBADAN | $72,495 | ICP1 |
| 2017 | Development of Nanomedicines for Tuberculosis Treatment1K43TW010371-01A1 · under PAR-17-001 | DUBE, ADMIRE | UNIVERSITY OF THE WESTERN CAPE | $69,798 | ICP1 |
| 2017 | Microbiota, Inflammation and Environmental Enteric Dysfunction (MiEED)1K43TW010697-01 · under PAR-17-001 | IQBAL, NAJEEHA TALAT | AGA KHAN UNIVERSITY (PAKISTAN) | $57,663 | ICP1 |
| 2016 | Gestational diabetes mellitus, gestational hypertension and risk of metabolic syndrome1K43TW010363-01 · under PAR-15-292 | OSOTI, ALFRED ONYANGO | UNIVERSITY OF NAIROBI | $113,240 | ICP1 |
| 2016 | Safety and Cognition in Driving (SCID): A proposal to examine functional driving skills in professional drivers in Cape Town.1K43TW010361-01 · under PAR-15-292 | GOUSE, HETTA-MARI | UNIVERSITY OF CAPE TOWN | $111,608 | ICP1 |
| 2016 | Real time Tuberculosis Medication Adherence Intervention in Rural Southwestern Uganda1K43TW010388-01 · under PAR-15-292 | MUSIIMENTA, ANGELLA | MBARARA UNIVERSITY/SCIENCE/ TECHNOLOGY | $98,717 | ICP1 |
| 2016 | Rotavirus vaccination in South Africa: safety and factors influencing the immune response to oral enteric vaccine1K43TW010382-01 · under PAR-15-292 | GROOME, MICHELLE JENNIFER | WITS HEALTH CONSORTIUM (PTY), LTD | $96,519 | ICP1 |
| 2016 | Pilot evaluation of a telephone-based psychosocial intervention package for perinatal depression in Nigeria1K43TW010400-01 · under PAR-15-292 | OLADEJI, BIBILOLA DAMILOLA | COLLEGE OF MEDICINE, UNIVERSITY OF IBADAN | $71,915 | ICP1 |
| 2016 | Humoral and adaptive immune responses study in Vibrio cholerae infection1K43TW010362-01 · under PAR-15-292 | BHUIYAN, MD TAUFIQUR RAHMAN | INTERNATIONAL CTR/DIARRHOEAL DIS RES | $71,661 | ICP1 |
| 2016 | Addressing barriers to Scaling-up Perinatal Mental Health Intervention1K43TW010399-01 · under PAR-15-292 | SIKANDER, SIHAM | HUMAN DEVELOPMENT RESEARCH FOUNDATION | $69,984 | ICP1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.